Version history

{
  "description": "Falsifiable prediction from high-scoring hypothesis (score=0.725, gene=S100B). Hypothesis: Can serum S100B serve as an early biomarker of BBB dysfunction in AD, preceding amyloid/tau pathology by >3 years, and does blocking S100B-RAGE signaling prevent pericyte dysfunction? Success criteria: 1. Serum S100B is elevated >2-fold in preclinical AD (CSF p-tau181 positive, PET negative) vs age-matched controls. 2. S100B-RAGE blockade (e.g., FPS-ZM1) restores pericyte coverage (NG2+/CD31+ ratio) in 5xFAD mice by >35%. 3. BBB integrity (MRI dynamic contrast enhancement) improves by >30% after 8-week RAGE inhibitor treatment. 4. Serum S100B correlates with MRI-measured BBB leakage area (r=0.65, p<0.001) in AD cohort.",
  "challenge_type": "hypothesis_resolve",
  "scope": "single_target",
  "initial_bounty_usd": 500,
  "current_bounty_usd": 500,
  "bounty_confidence": 0.5,
  "market_price": 0.5,
  "composite_score": 0.725,
  "debate_count": 0,
  "status": "open",
  "question": "Can serum S100B serve as an early biomarker of BBB dysfunction in AD, preceding amyloid/tau pathology by >3 years, and does blocking S100B-RAGE signaling prevent pericyte dysfunction?",
  "domain": "neurodegeneration",
  "triggered_by": "hypothesis-auto-create"
}